BPC-157 vs GHK-Cu

Side by side

BPC-157 Low and GHK-Cu Low are both graded low on our evidence scale. The table is read from our encyclopedia entries.

Two very different molecules

BPC-157 is a synthetic 15-amino-acid peptide derived from a protein in human gastric juice. It was developed by a research group in Zagreb, which has published most of its studies, and it is promoted for tendon, ligament, muscle and gut healing ¹.

GHK-Cu is three amino acids, glycine, histidine and lysine, bound to a copper ion. GHK occurs naturally in blood, and the peptide competes with albumin to carry copper ^{2 3}. It has been an ingredient in cosmetic 'copper peptide' creams for decades, and more recently has been sold as an injection.

BPC-157's evidence

BPC-157's case rests on animal studies. A 2025 orthopaedic systematic review found 36 eligible studies, 35 of them preclinical, showing improved healing in animal models of muscle, tendon, ligament and bone injury ⁴. In people, a two-person pilot found intravenous infusions tolerated without changes in standard blood markers ⁵, and a single-clinic chart review of knee injections in 16 patients, reached by phone, had no control group ⁶.

GHK-Cu's evidence

GHK-Cu's human evidence is topical. In a randomised trial of skin care after carbon dioxide laser resurfacing, 13 patients completed the study; computer analysis and blinded evaluators found no faster fading of redness and no difference in wrinkles between groups, although patients rated their skin quality higher with GHK-Cu ⁷. In animals, injected GHK-Cu increased collagen in implanted wound chambers in rats ⁸, reduced knee laxity after ligament reconstruction in rats ⁹, and reduced lung scarring in mice ¹⁰. No human study has tested GHK-Cu injected.

Why they end up in the same vial

Because both are marketed for 'healing', sellers combine them: GHK-Cu is the largest ingredient in the popular three- and four-peptide blends, at five times the amount of BPC-157. That makes the comparison practical. A person drawing a blend for its BPC-157 receives five times as much GHK-Cu, a peptide whose human evidence comes from skin creams. Our four-peptide blend page sets out the arithmetic, and no study has tested the two together.

Regulatory and sport status

Neither is FDA-approved. In July 2026, FDA's Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, to recommend adding BPC-157 to the list of substances pharmacies may use in compounding; FDA had not acted on that as of October 3, 2026 ¹¹. GHK-Cu's position is split: non-injectable GHK-Cu is in FDA's Category 1 for compounding, while injectable GHK-Cu cannot be compounded and is due before a second committee meeting by the end of February 2027 ¹¹. Our article on the second PCAC five covers what that meeting will consider. Both are prohibited at all times under the WADA Code, BPC-157 by name and GHK-Cu under the catch-all for non-approved substances ¹².

Safety questions

Neither peptide has a long-term human safety record by injection. BPC-157 is promoted for growing new blood vessels, which raises questions for people with a history of cancer; our article on BPC-157 and angiogenesis sets out the evidence. GHK-Cu delivers copper, and while topical use has a long cosmetic history, injected copper complexes have not been studied in people. Products sold for research use only are not made or tested for human use.

How the differences add up (as of October 3, 2026)

If the question is skin, GHK-Cu has small topical human studies with mixed results; BPC-157 has none. If the question is injuries, BPC-157 has a large animal literature and almost no human data; GHK-Cu has a few animal injury studies. For injected use, which is how both are sold, neither has a controlled human trial. Our ranking of peptides for tendon and ligament injuries puts both in context.

Frequently asked questions

What is the difference between BPC-157 and GHK-Cu?

BPC-157 is a 15-amino-acid fragment of a gastric protein promoted for injuries and gut healing; GHK-Cu is a copper-binding tripeptide promoted for skin and collagen. Their evidence comes from different kinds of study.

Which is better for healing?

Neither has a controlled human trial of injection. BPC-157 has many rodent injury studies; GHK-Cu's human studies are topical skin studies with mixed results.

Can you take BPC-157 and GHK-Cu together?

They are combined in commercial blends, but no study has tested them together in people or animals, and the blends contain far more GHK-Cu than BPC-157.

Related on Grey Peptides

• BPC-157
• GHK-Cu
• Blends and stacks

Sources

1. Seiwerth, S., et al. (2018). BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Curr Pharm Des, 24(18), 1972-1989. PMID: 29998800
2. Lau, S. J., et al. (1981). The interaction of copper(II) and glycyl-L-histidyl-L-lysine, a growth-modulating tripeptide from plasma. Biochem J, 199(3), 649-56. PMID: 7340824
3. Bossak-Ahmad, K., et al. (2021). Ternary Cu(2+) Complexes of Human Serum Albumin and Glycyl-l-histidyl-l-lysine. Inorg Chem, 60(22), 16927-16931. PMID: 34730942
4. Vasireddi, N., et al. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J, 21(4), 485-495. PMID: 40756949
5. Lee, E., et al. (2025). Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med, 31(5), 20-24. PMID: 40131143
6. Lee, E., et al. (2021). Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med, 27(4), 8-13. PMID: 34324435
7. Miller, T. R., et al. (2006). Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg, 8(4), 252-9. PMID: 16847171
8. Maquart, F. X., et al. (1993). In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. J Clin Invest, 92(5), 2368-76. PMID: 8227353
9. Fu, S. C., et al. (2015). Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction. J Orthop Res, 33(7), 1024-33. PMID: 25731775
10. Ma, W. H., et al. (2020). Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways. Life Sci, 241, 117139. PMID: 31809714
11. U.S. Food and Drug Administration. July 23-24, 2026 Pharmacy Compounding Advisory Committee: BPC-157 recommended 8-6-1; GHK-Cu (injectable) due at a second meeting before the end of February 2027; FDA 503A category list updated May 14, 2026 (non-injectable GHK-Cu in Category 1). Re-read October 3, 2026.
12. Grey Peptides dataset records for BPC-157 and GHK-Cu (status, WADA status, half-life and studied doses as sourced on each entry); read October 3, 2026.

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.